Drug Profile

AC 201 - Accropeutics

Alternative Names: AC-201- Accropeutics

Latest Information Update: 28 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Accropeutics
Class Anti-inflammatories; Antipsoriatics; Small molecules
Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Plaque psoriasis
Phase I Systemic lupus erythematosus; Unspecified
Preclinical Uveitis

Most Recent Events

06 Mar 2025 Pharmacokinetics data from a phase I trial in healthy volunteers released by Accropeutics
13 Feb 2025 Phase-I clinical trials in Systemic lupus erythematosus (PO) (Accropeutics pipeline, February 2025)
26 Nov 2024 Preclinical trials in Uveitis in China (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com